BiondVax (NASDAQ: BVXV), a biotechnology company focused on developing, manufacturing and commercializing innovative immunotherapeutic products, is working on changing the grim reality caused by the evolution of COVID-19. “The company’s leading inhaled nanosized antibody (‘NanoAb’) candidate, which is currently being prepared for clinical trials, has shown neutralization of all relevant Omicron subvariants… Developed in collaboration with Germany-based Max Planck Institute for Multidisciplinary Sciences (‘MPI’) and the University Medical Center Göttingen (‘UMG’), the alpaca-derived NanoAbs have demonstrated unique characteristics such as greater formulation advantages, stability at high temperatures, and binding affinity than monoclonal antibodies (‘mAbs’). Moreover, NanoAbs have shown strong potential for superior clinical outcomes, safety and patient convenience at lower costs than mAbs, which have generated billions in annual commercial sales,” a recent article reads. “Indeed, the emergence of new variants remains a concern, and NanoAb therapeutics have the potential to quickly and effectively address new variants,” CEO Amir Reichman is quoted as saying. “Our collaborators [at MPI and UMG] have generated libraries each with ~300 million COVID-19 NanoAb candidates, as compared to mAb libraries that contain only thousands of options. Thus, as new variants emerge, we would expect to be in a position to rapidly develop a new neutralizing NanoAb.”
To view the full article, visit https://ibn.fm/lQ8YI
About BiondVax Pharmaceuticals Ltd.
BiondVax is a biopharmaceutical company focused on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases. Since its inception, BiondVax has executed eight clinical trials including a seven-country, 12,400-participant phase 3 trial of its prior vaccine candidate and has built a state-of-the-art manufacturing facility for biopharmaceutical products. With highly experienced pharmaceutical industry leadership, BiondVax is aiming to develop a pipeline of diversified and commercially viable products and platforms beginning with an innovative nanosized antibody (“NanoAb”) pipeline. For more information, visit the company’s website at www.BiondVax.com.
NOTE TO INVESTORS: The latest news and updates relating to BVXV are available in the company’s newsroom at https://ibn.fm/BVXV
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.
As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
[email protected]
InvestorWire is part of the InvestorBrandNetwork